Enasidenib Nitroso Impurity 2
Synchemia is a leading Manufacturer in pharmaceutical Nitrosamine compounds.Enasidenib is used to treat acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation in patients who have not responded to other treatments or to those whose cancer has come back after treatment.Enasidenib Nitroso Impurity 2 is a highly toxic organic compound and a suspected human carcinogen. Handle the material carefully with proper safety measures.
Enasidenib Nitroso Impurity 2 CAS NO: NA chemically represented as N-(4-((2-Hydroxy-2-methylpropyl)(nitroso)amino)-6-(6-(trifluoromethyl)pyridin-2-yl)-1,3,5-triazin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)nitrous amide. Synchemia is the leading manufacturing and exporter of Enasidenib Nitroso Impurity 2 . We supply Enasidenib Nitroso Impurity 2 with detailed characterization data compliance with regulatory guidelines.
Make an Enquiry for Abacavir EP Impurity A
Related Products
| CAT No | SRC-N0143028 |
| CAS No | NA |
| Mol.F. | C12H19N3O |
| Mol.Wt. | 221.30 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143029 |
| CAS No | NA |
| Mol.F. | C10H10N2O4 |
| Mol.Wt. | 222.20 g/mole |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0143030 |
| CAS No | NA |
| Mol.F. | C13H19N3O2 |
| Mol.Wt. | 249.31 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143031 |
| CAS No | NA |
| Mol.F. | C11H15N3O2 |
| Mol.Wt. | 221.26 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143032 |
| CAS No | NA |
| Mol.F. | C12H17N3O2 |
| Mol.Wt. | 235.29 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143033 |
| CAS No | NA |
| Mol.F. | C14H21N3O2 |
| Mol.Wt. | 263.34 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143034 |
| CAS No | NA |
| Mol.F. | C14H20N4O4 |
| Mol.Wt. | 308.34 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143035 |
| CAS No | NA |
| Mol.F. | C13H17N3O4 |
| Mol.Wt. | 279.3 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143036 |
| CAS No | NA |
| Mol.F. | C13H17N3O4 |
| Mol.Wt. | 279.3 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143037 |
| CAS No | NA |
| Mol.F. | C14H17N3O5 |
| Mol.Wt. | 307.31 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143038 |
| CAS No | NA |
| Mol.F. | C14H19N3O4 |
| Mol.Wt. | 293.32 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143039 |
| CAS No | NA |
| Mol.F. | C11H15N3O3 |
| Mol.Wt. | 237.26 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143040 |
| CAS No | NA |
| Mol.F. | C10H13N3O3 |
| Mol.Wt. | 223.23 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143041 |
| CAS No | NA |
| Mol.F. | C12H15N3O4 |
| Mol.Wt. | 265.27 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143042 |
| CAS No | NA |
| Mol.F. | C9H10N2O2 |
| Mol.Wt. | 178.19 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143043 |
| CAS No | NA |
| Mol.F. | C17H24N4O6 |
| Mol.Wt. | 380.40 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |